Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc announces FDA approval of Orphan Drug Designation to Soliris (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients


Tuesday, 21 Jan 2014 06:30am EST 

Alexion Pharmaceuticals Inc:Says that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function (DGF) in renal transplant patients.Says DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation.Says In patients undergoing a kidney transplant, DGF leads to the patient requiring dialysis in order to survive. 1-3.